Moove It’s Health Index uses data to reveal the cities with the most developed healthtech ecosystems in the world and the software consulting firm recently ranked Vancouver third among Canadian cities for advancement of their healthtech sectors. Supporting Vancouver’s ranking as a global city leading the technological advancement of healthcare, the Healthcare Technology Report has announced […]
Zymeworks
What’s the Damage so Far? Breaking Down the 2022 Layoffs in BC Tech
Several thousand Canadians employed in the technology sector have been laid off this year, as a brief post-Pandemic surge has quickly soured into a global downturn. Layoffs hail from a wide range of companies, including Ottawa’s Shopify and Toronto’s Clearco. In all, more than 400 tech firms in North America have laid off staff in 2022. Several […]
Investment Firm Offers To Buy Zymeworks For USD $733 Million
Vancouver’s Zymeworks has received an unsolicited offer from investment firm All Blue Capital to acquire the publicly traded company for USD $10.50 per share, for a total of USD $773 million in cash. The proposal offers a share price more than twice the value at market close today. Dubai-based All Blue Capital currently owns close […]
New Zymeworks CEO Plans To Lay Off 25% Of Staff In 2022
Two weeks after being named the new CEO of Zymeworks, Kenneth Galbraith has announced major leadership changes and said the clinical-stage biopharmaceutical company will lay off at least 25% of its staff this year. Galbraith replaced Zymeworks co-founder Ali Tehrani, Ph.D., who has served as President and CEO since 2003. Dr. Tehrani will remain as […]
Zymeworks Announces Monster New Antibody Collaboration with Pharma Giant Merck
Vancouver-headquartered Zymeworks has signed a new license agreement with longtime partner Merck granting the pharmaceutical giant the right to develop additional multispecific antibody therapeutic candidates using Zymeworks’ Azymetric™ and EFECT™ platforms. Under the terms of the agreement, Zymeworks will provide Merck a worldwide, royalty-bearing license to research, develop and commercialize up to three new multispecific antibodies […]